Answers are grounded in this paper and cite their sources.
Analysis reveals clinical data indicating improved progression-free outcomes in histiocytic neoplasms with MEK1 mutations, suggesting ERK inhibition as a viable treatment strategy.
Research Watch| December 11 2025 RAF-independent MEK1-mutant Histiocytoses Respond to ERK Inhibition Available to Purchase Author & Article Information Online ISSN: 2159-8290 Print ISSN: 2159-8274 ©2025 American Association for Cancer Research2025American Association for Cancer Research Cancer Discov OF1. https://doi.org/10.1158/2159-8290.CD-RW2025-105 Views Icon Views Open Menu Article contents Figures & tables Video Audio Supplementary Material Peer Review Share Icon Share Facebook X LinkedIn Bluesky Email Tools Icon Tools Open Menu Get Permissions Cite Icon Cite Search Site Article Versions Icon Versions Proof December 11 2025 Citation RAF-independent MEK1-mutant Histiocytoses Respond to ERK Inhibition. Cancer Discov 2025; https://doi.org/10.1158/2159-8290.CD-RW2025-105 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest Search Advanced Search Mutations in mitogen-activated protein kinase (MAPK) signaling pathways are frequently found in histiocytic neoplasms, which comprise rare clonal disorders that can lead to aggressive tumorous lesions. The FDA-approved BRAF inhibitor vemurafenib has demonstrated strong efficacy in patients with BRAFV600E-mutant histiocytoses, with minimal cases of resistance. However, in patients with ERK-activating mutations with wild-type BRAF, inhibition of MEK1/2 showed less favorable outcomes. Patients who progress on BRAF and MEK inhibitors lack alternative treatment options. Thus, Diamond, Emile, Fujino, and colleagues utilized a large patient dataset and identified the MEK1E102_I103del mutation as a frequent and targetable alteration in histiocytoses. Analysis of genomic and clinical data from 498 patients with histiocytoses revealed that MEK1/2 mutations were the second most frequent alteration following BRAF, with the RAF-independent class 3 MEK1E102_I103del mutation being the most prevalent within this group. Notably, patients with class 3 MEK mutations had reduced progression-free... You do not currently have access to this content.
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: